FINWIRES · TerminalLIVE
FINWIRES

Xinhua Pharmaceutical Gets Trial Nod for Postoperative Pain Drug in China

By

Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) obtained approval for a clinical trial of its LXH-2103 injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.

The LXH-2103 injection was developed by the company to treat moderate to severe postoperative pain.

Related Articles